company background image
P0F logo

Egetis Therapeutics DB:P0F Stock Report

Last Price

€0.56

Market Cap

€170.8m

7D

1.5%

1Y

31.9%

Updated

26 Mar, 2024

Data

Company Financials +

Egetis Therapeutics AB (publ)

DB:P0F Stock Report

Market Cap: €170.8m

P0F Stock Overview

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment.

P0F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Egetis Therapeutics AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Egetis Therapeutics
Historical stock prices
Current Share Pricekr0.56
52 Week Highkr0.78
52 Week Lowkr0.30
Beta1.27
1 Month Change5.68%
3 Month Change10.71%
1 Year Change31.91%
3 Year Change-5.90%
5 Year Change-72.91%
Change since IPO-63.24%

Recent News & Updates

Recent updates

Shareholder Returns

P0FDE BiotechsDE Market
7D1.5%3.3%1.6%
1Y31.9%35.8%6.4%

Return vs Industry: P0F underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: P0F exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is P0F's price volatile compared to industry and market?
P0F volatility
P0F Average Weekly Movement9.9%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: P0F has not had significant price volatility in the past 3 months.

Volatility Over Time: P0F's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200629Nicklas Westerholmhttps://www.egetis.com

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.

Egetis Therapeutics AB (publ) Fundamentals Summary

How do Egetis Therapeutics's earnings and revenue compare to its market cap?
P0F fundamental statistics
Market cap€170.82m
Earnings (TTM)-€28.53m
Revenue (TTM)€5.03m

34.0x

P/S Ratio

-6.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
P0F income statement (TTM)
Revenuekr57.60m
Cost of Revenuekr204.50m
Gross Profit-kr146.90m
Other Expenseskr180.00m
Earnings-kr326.90m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 03, 2024

Earnings per share (EPS)-1.12
Gross Margin-255.03%
Net Profit Margin-567.53%
Debt/Equity Ratio19.9%

How did P0F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.